Access Now: AORN COVID-19 Clinical Support

Archive November 2018 XIX, No. 11

What's New in Cataract Medications

A look at 6 new drugs your surgeons might want to try.

Dan O

Dan O'Connor, Editor-in-Chief


In cataract surgery, there’s a drug for that. For dropless and for sutureless. For pre-op sedation and for pupil dilation. And, of course, for pain. Here’s a review of 6 relatively new medications your eye doctors might soon want to use. In alphabetical order: Dextenza, Dexycu, Inveltys, MKO Melt, Omidria and ReSure Sealant.


PUNCTUM PAIN INSERT Dextenza (dexamethasone insert) 0.4mg is a corticosteroid intracanalicular insert placed through the punctum for the treatment of ocular pain and inflammation following ophthalmic surgery.

Dextenza (dexamethasone insert) 0.4mg is a corticosteroid intracanalicular insert that the surgeon places through the punctum into the canaliculus to treat ocular pain. It’s designed to deliver a tapered dose of dexamethasone to the ocular surface for up to 30 days without preservatives, says Ocular Therapeutix. Following treatment, Dextenza is intended to resorb and exit the nasolacrimal system without the need for removal. Dextenza has completed Phase 3 evaluation for the treatment of ocular pain and inflammation following ophthalmic surgery, but is currently limited to investigational use only.


Dexycu (dexamethasone intraocular suspension) 9% is an extended-release steroid that replaces eye drops after cataract surgery with a single shot. The FDA-approved EyePoint Pharmaceuticals’s Dexycu in February. A single injection of Dexycu administered at the site of action at the conclusion of surgery treats post-op inflammation and dispenses with weeks of post-op eye drops. So-called dropless surgery benefits patients by eliminating noncompliance and dosing errors associated with the current practice of relying on the patient self-administering drops several times daily for weeks following cataract surgery, says the company.

EyePoint Pharmaceuticals
EXTENDED-RELEASE STEROID Dexycu is the first long-acting intracameral product approved by the FDA for treating inflammation following cataract surgery.

“Anything to reduce drops is a win-win for all of us,” says John Kraves, BSN, the ASC manager at Northwest Eye Surgeons in Renton, Wash.

New to Outpatient Surgery Magazine?
Sign-up to continue reading this article.
Register Now
Have an account? Please log in:
Email Address:
  Remember my login on this computer

advertiser banner

Other Articles That May Interest You

6 Exciting Developments in Cataract Surgery

These neat new innovations could propel the specialty to new heights.

What's New for Your Cataract Procedures

In search of better surgical outcomes at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting.

Pointers to Prevent Posterior Capsular Rupture

Devices and drugs to avoid the complication every cataract surgeon dreads - when the capsular bag unexpectedly breaks during the case.